US equities
|
MU
$969.78
▲+4.42%
META
$614.00
▼-1.00%
TSLA
$402.26
▼-1.28%
SPCX
$144.83
▼-2.52%
NVDA
$217.53
▼-0.19%
SNDK
$1,380.00
▲+5.76%
SKHY
$163.87
▲+12.73%
STX
$683.58
▲+2.36%
MU
$969.78
▲+4.42%
META
$614.00
▼-1.00%
TSLA
$402.26
▼-1.28%
SPCX
$144.83
▼-2.52%
NVDA
$217.53
▼-0.19%
SNDK
$1,380.00
▲+5.76%
SKHY
$163.87
▲+12.73%
STX
$683.58
▲+2.36%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Cullinan Therapeutics, Inc. - Common Stock
(NQ:
CGEM
)
15.25
+0.41 (+2.76%)
Delayed Quote
Updated: 12:54 PM EDT, Oct 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cullinan Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead
↗
Today 9:45 EDT
Almonty Industries, Kopin and Cullinan Therapeutics trade under $20, and each faces a near-term catalyst: China tungsten curbs, CES and a February FDA decision.
Via
MarketBeat
Topics
Artificial Intelligence
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
October 27, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases
October 19, 2026
From
Taiho Oncology, Inc.
Via
Business Wire
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
October 08, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics (NASDAQ:CGEM) Shares Jump on Inline Q2 Earnings and Pipeline Milestones
↗
August 06, 2026
Via
Chartmill
Cullinan Therapeutics (NASDAQ:CGEM) Posts Narrower Q1 Loss, Eyes Key Clinical Data Catalysts
↗
May 07, 2026
Via
Chartmill
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
October 01, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
↗
September 28, 2026
Cullinan Therapeutics (NASDAQ:CGEM) outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978...
Via
MarketBeat
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
September 24, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
September 21, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
September 14, 2026
Company to host a virtual event today at 8:00 a.m. ET
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
September 13, 2026
From
Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. and Cullinan Therapeutics, Inc.
Via
Business Wire
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
September 10, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
August 19, 2026
From
Taiho Oncology, Inc.
Via
Business Wire
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
August 12, 2026
From
Taiho Oncology, Inc.
Via
Business Wire
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 06, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
July 28, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
June 10, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
↗
June 08, 2026
href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell...
Via
Benzinga
Topics
Stocks
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
June 06, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
May 26, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
May 19, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
May 18, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 07, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
April 28, 2026
From
Taiho Oncology, Inc.
Via
Business Wire
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 10, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
February 18, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 05, 2026
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen)
↗
January 15, 2026
Via
Chartmill
< Previous
1
2
3
4
5
6
7
Next >
